LINC01301

Across TCGA pan-cancer cohorts, LINC01301 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of LINC01301’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LINC01301 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01301 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, COAD, and LUAD are the cancer types where LINC01301 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01301 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	II,III,IV	−0.318	<.001	11	view →
COAD	Female	II,III,IV	+0.609	<.001	10	view →
LUAD	Male	All	+0.356	<.001	9	view →
KICH	Female	II,III,IV	−0.678	<.001	8	view →
LIHC	Male	III,IV	+0.356	<.001	8	view →
LUSC	Female	All	+0.450	<.001	6	view →
BRCA	All	III,IV	−0.436	<.001	6	view →
KIRC	Male	All	−0.281	<.001	6	view →
STAD	All	All	+0.295	.007	4	view →
CHOL	All	All	+0.562	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

LINC01301–THCA

Open the THCA breakdown →